(NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced additional results showing a statistically significant reduction in new varices in per-protocol ...

Galectin Therapeutics Inc. Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices with belapectin vs placebo ...

untreated or incompletely treated esophageal and/or gastric varices with bleeding or at high risk for bleeding; and prior bleeding due to esophageal and/or gastric varices within 6 months of study ...